Latest Revenue Streaming News

Delorean Corporation has locked in a $14.5 million lower-cost loan facility with National Australia Bank to fund its SA1 Salisbury Bioenergy Project, refinancing existing debt and freeing capital for further bioenergy developments.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

Clover Corp has reported a standout FY25 with robust revenue and profit growth, driven by new product launches and strategic investments that strengthen its global supply chain and market reach.

Clover Corporation Limited has reported a robust financial year ending July 2025, with revenue climbing 38% and net profit soaring to $7 million. The company also announced a higher fully franked final dividend, reflecting its strengthened financial position.

ReNerve Ltd has launched its Empliq product range, marking its entry into the dermal and amniotic tissue repair markets with first sales already recorded and a US launch planned.

ChemX Materials Limited has entered voluntary administration following a turbulent quarter marked by convertible note amendments, a trading suspension, and ongoing funding challenges.

Scout Security reports a significant 48% reduction in operating cash outflows for the June quarter, while holding just $78,000 in cash and advancing talks to acquire Roo Inc. The company is navigating funding challenges amid an ongoing ASX trading suspension.

Scout Security reported a significant 62% reduction in operating cash outflows for Q3 FY2025, while advancing a potential acquisition and partnership opportunities following CES. The company’s cash position remains tight, prompting ongoing capital raising efforts.

Scout Security reports a 52% jump in quarterly cash receipts and a 31% reduction in operating outflows, while advancing plans to acquire New York’s Roo Inc.

Platinum Asset Management confirms the Independent Expert's valuation of its proposed merger with L1 Capital remains unchanged after reviewing updated financials, with the Board unanimously recommending shareholder approval.

Atlas Arteria has announced a 20.0 cents per stapled security distribution for the first half of 2025, with payments scheduled for early October. The distribution reflects the company’s ongoing commitment to delivering steady returns from its international toll road assets.

Atlas Arteria has announced an ordinary dividend of AUD 0.20 per security for the six months ending June 2025, payable in early October. The dividend is fully unfranked, reflecting the company’s international income streams.